Late-Breaking Clinical Science Abstracts


Deadline to submit a Late Breaking Clinical Science Abstract: Tuesday, 17 October, 2023 at 11:59 p.m. EDT

Submitted abstracts can be edited until the deadline.

Late-Breaking Clinical Science submissions are intended to facilitate the presentation of high-impact multi-center studies or particularly provocative single-center investigations. In general, such studies would include prospective, randomized trials that seek to investigate new approaches to the diagnosis and/or treatment of cardiothoracic diseases relevant to the field and that have the potential to alter our contemporary treatment paradigm.

To assure that truly "late-breaking" research is considered for presentation at the meeting, your abstract can be submitted if it describes a trial or study that will not have results and conclusions available by 17 October, 2023 but WILL have results and conclusions by 20 March, 2024.

All late-breaking abstracts must be submitted by the 17 October deadline and will serve as a placeholder for the final abstract.
  •   A study which has results and conclusions by 17 October, 2023 is not considered late-breaking and should be submitted as a research abstract.
  •   A late-breaking abstract presenting an interim analysis of clinical trial data will not be accepted unless the intention to conduct an interim analysis was predetermined in the trial protocol before the study commenced.
  •   All late-breaking abstracts accepted for presentation must undergo a final review of the study results and conclusions by the Executive Program Committee. Results will be kept confidential until presentation.
  •   ISHLT reserves the final decision regarding scheduling of Late-Breaking Clinical Science presentations.
A Late-Breaking Clinical Science submission is separated into the following SUBMISSION STEPS:
When entering the Title of your abstract, keep in mind that the abstract is limited to a total of 2,140 characters (not including spaces), INCLUDING the abstract title.
Author information does not count towards the character limit.

The authors included should be those who contribute significantly to the intellectual content of the abstract (maximum 50 authors). When adding authors to your abstract, the Full Name, Degree, Affiliation, and Email Address of each author must be included. You will be able to use the ISHLT database search tool on the submission site to search and add your authors. Authors will be listed in the author block in the order they are added but can be rearranged after adding.

The Submitting Author is responsible for notifying all named co-authors that they will be listed as a co-author on a submitted abstract.

The Presenting Author will be the only author to receive notification of acceptance/rejection of a submitted abstract; therefore, it is the Presenting Author's responsibility to notify all co-authors regarding the outcome of an abstract submission. If the abstract is accepted for presentation at the ISHLT2024 Annual Meeting, the Presenting Author must register for the meeting and attend in person. If a change in Presenting Author must be made after the submission deadline, the Presenting Author will be given the opportunity to do so in January 2024.
Your abstract may be submitted into only one category. Submission of the same abstract into multiple categories is not permitted. Submission of one study as several different abstracts is also not permitted. If the abstracts in question are not different enough to be considered separate studies, or if the same abstract is submitted into multiple categories, all versions may be rejected.

Abstract Submission Categories are separated into four Core Therapies:
  •   HEART (Advanced Heart Failure and Transplantation)
  •   LUNG (Advanced Lung Failure and Transplantation)
  •   MCS (Mechanical Circulatory Support)
  •   PVD (Pulmonary Vascular Disease (PAH and CTEPH)
You will be asked to select the Primary Practice Area most relevant to your research abstract, as well as any additional practice areas applicable.
  •   Anesthesiology and Critical Care
  •   Cardiology
  •   Cardiothoracic Surgery
  •   Infectious Diseases
  •   Nursing and Allied Health
  •   Pathology
  •   Pediatrics
  •   Pharmacy and Pharmacology
  •   Pulmonology
  •   Research and Immunology
During abstract submission, the following questions will be asked:

* Is the presenting author an employee or owner of a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products? (Yes/No)

* Is this abstract being funding (in part or in whole) by a healthcare company? (Yes/No)
In this step, the abstract body (purpose, methods, results, and conclusions) and any tables or images are entered. Abstract submission content should include:
  •   Brief statement of Purpose of the study (goal or hypothesis being tested)
  •   Methods and procedures used
  •   Endpoints
  •   2140 characters (spaces are ignored)
  •   Includes characters in the Abstract Title, Abstract Body, Table(s), and Image(s).
  •   Includes characters in the default headings Purpose, Methods, and Endpoints.
  •   A Table/Image removes 320 characters from your character limit. The amount of data in the table does not make a difference to the character count.
  •   Author names and institutions are not counted in the character limit.
  •   Proofread abstracts carefully to avoid errors before submission.
  •   You may return to your abstract to make corrections to any portion of the abstract submission, including authors, up until the submission deadline.
  •   Corrections are not permitted after the submission deadline.
A $25 (USD) processing fee must accompany each abstract. ISHLT accepts payment only in the form of MasterCard, Visa and American Express. Purchase orders, checks, and electronic bank transfers will not be accepted. This fee is non-refundable and used to cover the cost of submission and processing.
A disclosure statement must be collected from the Submitting Author. If the abstract is accepted, a disclosure will be collected from the Presenting Author (if different from the Submitting Author).
If all submission steps are completed, the submission is marked COMPLETE and no further action is required but abstracts can still be edited by the submitter until the deadline.

If one or more submission steps are not completed, the system will indicate which steps must be finished before the submission is marked COMPLETE.

If you are ready to submit your Late-Breaking Clinical Science Abstract, click the login button below. Once logged in, you will be required to submit (or update) your Conflict of Interest Disclosure on the site before beginning your abstract submission.

For Technical Support please contact:
CTI Meeting Technologies
The support desk is manned from 8:00 a.m. – 5:00 p.m. CDT, Monday-Friday (excluding holidays)

For general submission questions please contact:
Susie Newton, ISHLT Scientific Programs Manager